Diabetes is a common comorbidity among patients with head and neck cancer (HNC). In this study using SEER‑Medicare data, investigators report both prevalence at cancer diagnosis and cumulative incidence of Type 2 diabetes more than 1 year after diagnosis among older (≥66 years) patients. Reported cumulative incidences >1 year after diagnosis ranged from 7% to 14% across most Asian, Native Hawaiian, and Pacific Islander (ANHPI) subgroups, with South Asian survivors having the highest observed incidence (19.4%). Non‑Hispanic White (NHW) HNC survivors had a 7.5% incidence in this period. Figure 1 in the article illustrates prevalence at diagnosis and incidence >1 year after diagnosis and notes cell‑size suppression where n < 11 according to CMS policy.
The analysis identified HNC patients aged 66 years or older from the SEER‑Medicare linked database covering diagnoses from 2000 through 2019. The analytic sample sizes reported in the abstract included 2,862 older NHW patients and ANHPI subgroups of 423 East Asian, 211 Southeast Asian, 139 South Asian, and 68 Native Hawaiian and Pacific Islander (NHPI) survivors. The investigators compared ANHPI subgroups to multiple reference groups, including NHW, East Asian, and Chinese HNC patients. The abstract does not provide additional details on inclusion/exclusion criteria, comorbidity measures, or treatment variables; those specifics were not reported in the abstract.
To estimate risk of developing Type 2 diabetes, the authors used Fine‑Gray subdistribution hazard models to account for competing risks. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported for ANHPI subgroups versus reference groups. Comparisons focused on diabetes incidence occurring more than one year after the cancer diagnosis. The abstract does not list the full set of covariates included in models; that information was not reported in the abstract.
South Asian HNC survivors: highest observed cumulative incidence >1 year after diagnosis at 19.4% and elevated hazard compared with NHW (HR 3.34; 95% CI 1.86–6.00).
East Asian HNC survivors: cumulative incidence reported at 14.0% and increased hazard relative to NHW (HR 2.04; 95% CI 1.36–3.06).
Other ANHPI subgroups: reported incidence ranged from about 7% to 14%; sample sizes varied and were smaller for some subgroups.
NHW HNC survivors: cumulative incidence >1 year after diagnosis reported as 7.5%.
The authors observed that elevated diabetes risk was particularly notable among Chinese and Asian Indian/Pakistani HNC survivors in subgroup comparisons. Overall, ANHPI HNC survivors demonstrated an approximately 2‑ to 3‑fold higher risk of developing Type 2 diabetes relative to NHW survivors in the period examined.
The analysis identifies a marked disparity in incident Type 2 diabetes among older ANHPI HNC survivors compared with NHW survivors, with particularly high incidence and relative risk in South Asian and East Asian subgroups. These findings suggest clinicians and survivorship programs should consider heightened surveillance for diabetes and targeted prevention interventions in ANHPI HNC patients, especially those of South and East Asian descent. The authors emphasize the need for diabetes prevention strategies tailored to these high‑risk groups within HNC survivorship care.
The abstract highlights several limitations to interpretation. Several ANHPI subgroups had small sample sizes (for example, Korean, Vietnamese, and NHPI subgroups had fewer than 100 HNC patients), which constrains precision and generalizability. CMS cell‑size suppression policy also led to suppression of small cell counts (n < 11) in reported figures. The abstract does not report the full set of covariates adjusted for in the Fine‑Gray models or additional methodological details such as how diabetes was ascertained from claims, so those specifics were not available in the abstract. Readers should interpret subgroup comparisons, particularly for groups with small counts, with caution.
In a SEER‑Medicare analysis of older HNC survivors diagnosed 2000–2019, ANHPI patients—particularly South Asian and East Asian survivors—had substantially higher incidence and hazards of developing Type 2 diabetes more than one year after cancer diagnosis compared with non‑Hispanic White survivors. The study reports a roughly 2‑ to 3‑fold difference in diabetes risk for ANHPI versus NHW HNC survivors and calls for focused diabetes prevention efforts for high‑risk ANHPI subgroups. The abstract notes no conflicts of interest. Details on model covariates and full methods are not reported in the abstract and would require consulting the full text.